Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Kyverna Therapeutics a “Moderate Buy” consensus: Five of six analysts rate the stock a buy, while one recommends selling. The average 12-month price target is $30, compared with the recent price of $8.08.
• Institutional ownership has increased: Hedge funds and other institutions own 18.08% of KYTX, with AIGH Capital Management and Renaissance Technologies notably expanding their positions.
• Kyverna reported a quarterly loss of $0.63 per share, beating the consensus estimate of a $0.68 loss. The clinical-stage biotechnology company is developing engineered regulatory T-cell therapies for autoimmune and inflammatory diseases.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $30.00.

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYTX. RFG Advisory LLC purchased a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at about $4,185,000. AIGH Capital Management LLC grew its stake in Kyverna Therapeutics by 33.3% during the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company's stock worth $17,260,000 after buying an additional 500,000 shares during the last quarter. Renaissance Technologies LLC grew its stake in Kyverna Therapeutics by 106.6% during the 1st quarter. Renaissance Technologies LLC now owns 367,492 shares of the company's stock worth $3,171,000 after buying an additional 189,593 shares during the last quarter. Simplify Asset Management Inc. acquired a new position in Kyverna Therapeutics during the fourth quarter worth approximately $1,808,000. Finally, Maven Securities LTD acquired a new position in Kyverna Therapeutics during the fourth quarter worth approximately $1,376,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Stock Up 0.4%

Kyverna Therapeutics stock opened at $8.08 on Friday. Kyverna Therapeutics has a 1-year low of $3.27 and a 1-year high of $13.67. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The stock has a market cap of $499.67 million, a PE ratio of -2.75 and a beta of 1.93. The stock's fifty day moving average is $8.06 and its two-hundred day moving average is $8.44.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.05. On average, sell-side analysts expect that Kyverna Therapeutics will post -2.78 EPS for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source